JP2008528033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528033A5 JP2008528033A5 JP2007553266A JP2007553266A JP2008528033A5 JP 2008528033 A5 JP2008528033 A5 JP 2008528033A5 JP 2007553266 A JP2007553266 A JP 2007553266A JP 2007553266 A JP2007553266 A JP 2007553266A JP 2008528033 A5 JP2008528033 A5 JP 2008528033A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- nucleic acid
- polypeptide
- acid molecule
- heterologous polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims 26
- 102000040430 polynucleotide Human genes 0.000 claims 17
- 108091033319 polynucleotide Proteins 0.000 claims 17
- 239000002157 polynucleotide Substances 0.000 claims 17
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 14
- 238000000034 method Methods 0.000 claims 6
- 230000028327 secretion Effects 0.000 claims 6
- 210000004962 mammalian cell Anatomy 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000003248 secreting effect Effects 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 108010042106 Collagen Type IX Proteins 0.000 claims 2
- 102000004427 Collagen Type IX Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 229940088598 enzyme Drugs 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 108091005703 transmembrane proteins Proteins 0.000 claims 2
- 102000035160 transmembrane proteins Human genes 0.000 claims 2
- 108090001008 Avidin Proteins 0.000 claims 1
- 102100040512 Collagen alpha-1(IX) chain Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000007437 Fetuin-B Human genes 0.000 claims 1
- 108010086121 Fetuin-B Proteins 0.000 claims 1
- 101000749901 Homo sapiens Collagen alpha-1(IX) chain Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000008072 Lymphokines Human genes 0.000 claims 1
- 108010074338 Lymphokines Proteins 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 claims 1
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 claims 1
- 229960000723 ampicillin Drugs 0.000 claims 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 229950010131 puromycin Drugs 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64701305P | 2005-01-27 | 2005-01-27 | |
| PCT/US2006/002951 WO2006081430A2 (en) | 2005-01-27 | 2006-01-27 | Leader sequences for directing secretion of polypeptides and methods for production thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009009381A Division JP2009131268A (ja) | 2005-01-27 | 2009-01-19 | ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528033A JP2008528033A (ja) | 2008-07-31 |
| JP2008528033A5 true JP2008528033A5 (https=) | 2009-03-05 |
Family
ID=36741080
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007553266A Pending JP2008528033A (ja) | 2005-01-27 | 2006-01-27 | ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 |
| JP2009009381A Pending JP2009131268A (ja) | 2005-01-27 | 2009-01-19 | ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009009381A Pending JP2009131268A (ja) | 2005-01-27 | 2009-01-19 | ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080286834A1 (https=) |
| EP (1) | EP1841874B1 (https=) |
| JP (2) | JP2008528033A (https=) |
| AT (1) | ATE454455T1 (https=) |
| AU (1) | AU2006207999A1 (https=) |
| CA (1) | CA2589895A1 (https=) |
| DE (1) | DE602006011574D1 (https=) |
| DK (1) | DK1841874T3 (https=) |
| WO (1) | WO2006081430A2 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| ES2543341T3 (es) | 2005-09-13 | 2015-08-18 | National Research Council Of Canada | Métodos y composiciones para modular la actividad de células tumorales |
| US9060961B2 (en) * | 2006-11-09 | 2015-06-23 | University Of Washington | Molecules and methods for treatment and detection of cancer |
| WO2009056330A1 (en) * | 2007-10-31 | 2009-05-07 | Eth Zurich | Soluble truncated apom proteins and medical uses thereof |
| EP2271358B1 (en) * | 2008-03-25 | 2018-11-21 | Amarantus Therapeutics, Inc. | use of mesencephalic astrocyte-derived neurotrophic factor for treating Parkinson's disease |
| FR2933773B1 (fr) * | 2008-07-10 | 2013-02-15 | Biomerieux Sa | Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal |
| EP2318529B1 (en) | 2008-08-04 | 2017-10-18 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
| WO2010075194A1 (en) * | 2008-12-22 | 2010-07-01 | St. Jude Children's Research Hospital | Prokaryotic expression of soluble, active dkk |
| JP2010183885A (ja) * | 2009-02-13 | 2010-08-26 | Kobe Univ | タンパク質の製造方法およびそれに用いる発現ベクター |
| US8445445B2 (en) | 2009-09-15 | 2013-05-21 | Five Prime Therapeutics, Inc. | Method of promoting hair growth using FGFR4 extracellular domains |
| LT2498799T (lt) | 2009-11-13 | 2016-11-10 | Five Prime Therapeutics, Inc. | Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis |
| EA034462B1 (ru) | 2009-11-24 | 2020-02-11 | Алетиа Байотерапьютикс Инк. | Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований |
| WO2011084711A2 (en) | 2009-12-17 | 2011-07-14 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr3 extracellular domains |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| DK2585098T3 (da) | 2010-06-28 | 2014-11-03 | Five Prime Therapeutics Inc | Ekstracellulære FZD8-domæner og fusionsmolekyler fraekstracellulære FZD8-domæner til anvendelse ved behandling afobesitet og obesitet-relaterede lidelser |
| EP2444495A1 (en) * | 2010-10-20 | 2012-04-25 | Algenics | Secretion of recombinant polypeptides in the extracellular medium of diatoms |
| KR101910779B1 (ko) | 2010-11-15 | 2018-10-22 | 파이브 프라임 테라퓨틱스, 인크. | Ｆｇｆｒ１ 세포밖 도메인 조합치료 |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| AU2012205384B2 (en) | 2011-01-14 | 2015-09-10 | Five Prime Therapeutics, Inc. | IL-27 antagonists for treating inflammatory diseases |
| CN107823630A (zh) | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
| US9822170B2 (en) | 2012-02-22 | 2017-11-21 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| EP2858679B2 (en) | 2012-06-08 | 2024-06-05 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| EP4331620A3 (en) | 2012-12-07 | 2024-12-04 | Translate Bio, Inc. | Lipidic nanoparticles for mrna delivery |
| EP2970940B1 (en) | 2013-03-14 | 2018-07-25 | Translate Bio, Inc. | Mrna therapeutic compositions and use to treat diseases and disorders |
| KR102516152B1 (ko) | 2013-08-01 | 2023-03-31 | 파이브 프라임 테라퓨틱스, 인크. | 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 |
| SG11201610672YA (en) | 2014-06-23 | 2017-01-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| EP3212670B1 (en) | 2014-10-29 | 2020-12-23 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| MX2017008218A (es) | 2014-12-22 | 2017-10-18 | Five Prime Therapeutics Inc | Anticuerpos anti-csf1r para tratar pvns. |
| RS60614B1 (sr) | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| AU2016249981B2 (en) | 2015-04-13 | 2022-02-17 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| AU2016342269A1 (en) | 2015-10-22 | 2018-03-29 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
| ES2981471T3 (es) | 2016-04-25 | 2024-10-09 | Five Prime Therapeutics Inc | NOPE para el tratamiento de la pérdida de masa muscular y la debilidad muscular patológicas |
| HRP20211703T1 (hr) | 2016-11-02 | 2022-02-04 | Jounce Therapeutics, Inc. | Protutijela protiv pd-1 i njihova upotreba |
| CN109906030B (zh) | 2016-11-04 | 2022-03-18 | 安健基因公司 | 用于产生仅重链抗体的经基因修饰的非人动物和方法 |
| TWI685351B (zh) * | 2016-12-29 | 2020-02-21 | 財團法人生物技術開發中心 | 延長蛋白質藥物體內半衰期的激肽原-1衍生胜肽 |
| CN110709420A (zh) | 2017-03-31 | 2020-01-17 | 戊瑞治疗有限公司 | 使用抗gitr抗体的癌症组合疗法 |
| US20200024351A1 (en) | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
| AU2018281334A1 (en) | 2017-06-06 | 2019-12-19 | Kindred Biosciences, Inc. | Erythropoietin and analogs for veterinary use |
| EA202091540A1 (ru) | 2017-12-22 | 2021-03-22 | Джаунс Терапьютикс, Инк. | Антитела к lilrb2 |
| CN113056483B (zh) | 2018-07-09 | 2025-08-01 | 戊瑞治疗有限公司 | 结合到ilt4的抗体 |
| US20220112257A1 (en) * | 2019-01-11 | 2022-04-14 | Arbele Limited | Mul tispecific prochemokine therapeutic proteins (park) and method of making and using thereof |
| US20220152098A1 (en) | 2019-03-01 | 2022-05-19 | Achelois Biopharma, Inc. | Methods of modulating cd160 function in the antigen-specific immune cell and uses thereof |
| WO2021178001A1 (en) * | 2020-03-05 | 2021-09-10 | Curie Co. Inc. | Methods for cell free protein expression of mature polypeptides derived from zymogens and proproteins |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| CN116724051A (zh) | 2020-08-10 | 2023-09-08 | 上海寻百会生物技术有限公司 | 用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法 |
| WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5712114A (en) * | 1995-06-06 | 1998-01-27 | Basf Aktiengesellschaft | Compositions for expression of proteins in host cells using a preprocollagen signal sequence |
| DK1105508T3 (da) * | 1998-08-17 | 2003-01-06 | Europ Lab Molekularbiolog | Fremgangsmåde til oprensning af biomolekyle- eller proteinkomplekser |
| US20080242603A1 (en) * | 2004-02-20 | 2008-10-02 | Yan Wang | Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use |
| EP2479277B1 (en) * | 2004-07-22 | 2015-09-02 | Five Prime Therapeutics, Inc. | Use of MGD-CSF in a method of treatment of Alzheimer's disease. |
-
2006
- 2006-01-27 CA CA002589895A patent/CA2589895A1/en not_active Abandoned
- 2006-01-27 EP EP06719694A patent/EP1841874B1/en not_active Expired - Lifetime
- 2006-01-27 DE DE602006011574T patent/DE602006011574D1/de not_active Expired - Lifetime
- 2006-01-27 WO PCT/US2006/002951 patent/WO2006081430A2/en not_active Ceased
- 2006-01-27 DK DK06719694.9T patent/DK1841874T3/da active
- 2006-01-27 AT AT06719694T patent/ATE454455T1/de not_active IP Right Cessation
- 2006-01-27 AU AU2006207999A patent/AU2006207999A1/en not_active Abandoned
- 2006-01-27 JP JP2007553266A patent/JP2008528033A/ja active Pending
- 2006-01-27 US US11/883,065 patent/US20080286834A1/en not_active Abandoned
-
2009
- 2009-01-19 JP JP2009009381A patent/JP2009131268A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528033A5 (https=) | ||
| EP1841874B1 (en) | Leader sequences for directing secretion of polypeptides and methods for production thereof | |
| JP2553058B2 (ja) | 真核性のバラスト部分を有する融合タンパク質 | |
| ES2732907T3 (es) | Procedimiento de expresión | |
| HRP20230991T1 (hr) | Inzulin-fc fuzijski proteini ultradugog djelovanja i metode uporabe | |
| RU2017123283A (ru) | Партнеры по слиянию для получения пептидов | |
| CN114981450A (zh) | 人工纳米孔及其相关用途和方法 | |
| CN104725515B (zh) | 一种类弹性蛋白多肽与柯萨奇腺病毒受体融合蛋白及其制备方法和应用 | |
| JP2019521643A5 (https=) | ||
| US20180099994A1 (en) | Nucleic acid construct | |
| TW200732472A (en) | Method for the recombinant expression of a polypeptide | |
| JP2019514361A5 (https=) | ||
| JP2016505251A5 (https=) | ||
| AU2011218243A1 (en) | Fibronectin based scaffold domain proteins that bind IL-23 | |
| RS61391B1 (sr) | Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti | |
| CA2636075A1 (en) | Chimaeric fusion protein with superior chaperone and folding activities | |
| US11053278B2 (en) | Tangential flow filtration based protein refolding methods | |
| CN101899489A (zh) | 利用内含肽反式剪接模式化生产融合蛋白质 | |
| CN101967493A (zh) | 一种原核表达载体及其应用 | |
| Zhang et al. | Fusion partners as a tool for the expression of difficult proteins in mammalian cells | |
| US9803207B2 (en) | Expression vector for production of recombinant proteins in prokaryotic host cells | |
| JP2003504020A5 (https=) | ||
| JP2019516371A5 (https=) | ||
| JP2015510770A5 (https=) | ||
| CN104130308A (zh) | 一种蛋白质定点peg修饰的方法及所得peg修饰的蛋白质 |